TW200510386A - Treatment of excessive osteolysis with indolinone compounds - Google Patents

Treatment of excessive osteolysis with indolinone compounds

Info

Publication number
TW200510386A
TW200510386A TW093104637A TW93104637A TW200510386A TW 200510386 A TW200510386 A TW 200510386A TW 093104637 A TW093104637 A TW 093104637A TW 93104637 A TW93104637 A TW 93104637A TW 200510386 A TW200510386 A TW 200510386A
Authority
TW
Taiwan
Prior art keywords
treatment
indolinone compounds
compounds
excessive osteolysis
osteolysis
Prior art date
Application number
TW093104637A
Other languages
English (en)
Inventor
Lesley Murray
Farrell Anne Marie O'
Tinya Abrams
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of TW200510386A publication Critical patent/TW200510386A/zh

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093104637A 2003-02-24 2004-02-24 Treatment of excessive osteolysis with indolinone compounds TW200510386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24

Publications (1)

Publication Number Publication Date
TW200510386A true TW200510386A (en) 2005-03-16

Family

ID=36703964

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104637A TW200510386A (en) 2003-02-24 2004-02-24 Treatment of excessive osteolysis with indolinone compounds

Country Status (3)

Country Link
CN (1) CN1758914A (zh)
TW (1) TW200510386A (zh)
ZA (1) ZA200506371B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389562B2 (en) * 2007-12-12 2013-03-05 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate

Also Published As

Publication number Publication date
CN1758914A (zh) 2006-04-12
ZA200506371B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
MXPA05008961A (es) Tratamiento de osteolisis excesiva con compuestos de indolinona.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
SG10201811480WA (en) Therapeutic compounds and compositions
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MY163852A (en) Amidophenoxyindazoles useful as inhibitors of c-met.
MY147364A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
GB2430935A (en) Tetrapeptide analogs
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
TW200621230A (en) Anti-tumor compounds
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
TW200510301A (en) Novel compounds
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
TW200626068A (en) Active compounds for seed treatment
TW200716141A (en) Compositions and methods for treatment for neoplasms
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
MX2009013069A (es) Tratamiento de leucemia resistente al imatinib.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
UA96745C2 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung